Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

Winden, Annemieke W.J. Opstal‐van; Krop, Esmeralda; Kåredal, Monica; Gast, Marie-Christine W.; Lindh, Christian; Jeppsson, Marina C.; Jönsson, Bo; Grobbee, Diederick E.; Peeters, Petra H.M.; Beijnen, Jos H.; Gils, Carla H. van; Vermeulen, Roel

doi:10.1186/1471-2407-11-381

Cited by 78 publications

(49 citation statements)

References 35 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…α-2-macroglobulin and ceruloplasmin proteins have previously been identified as downregulated in the plasma of women 21 months prior to the diagnosis of breast cancer (36), as well as in the serum pool of women with IDC (HER2-positive) who were treated with neoadjuvant chemotherapy (37). Moreover, the level of the plasma concentration of α-2-macroglobulin and ceruplasmin proteins appeared to be upregulated in the plasma pool of the IDC group in the present study.…”

Section: Discussionsupporting

confidence: 54%

Proteomic profile of saliva and plasma from women with impalpable breast lesions

et al. 2016

View full text Add to dashboard Cite

Abstract. The present study evaluated the proteomic profile of saliva and plasma from women with impalpable breast lesions using nano-liquid chromatography-quadrupole-time-of-flight (nLC-Q-TOF) technology. Plasma and saliva from patients with fibroadenoma (n=10), infiltrating ductal carcinoma (n=10) and healthy control groups (n=8) were assessed by combinations of inter/intra-group analyses, revealing significant quantitative and qualitative differences. The major differentially-expressed proteins in the saliva of patients compared with the controls were α2-macroglobulin and ceruloplasmin, but the proteins that met the minimum fold-change and P-value cut-offs were leukocyte elastase inhibitor and α-enolase, and deleted in malignant brain tumors 1. Concerning plasma, α-2-macroglobulin and ceruplasmin were upregulated, while other proteins such as haptoglobin, hemopexin and vitamin D-binding protein were downregulated compared with the control. The changes in immune, molecular transport and signaling pathways were the most representative in the proteomic profile of the saliva and plasma. This is the first study to describe the proteome of saliva and plasma from the same women with impalpable breast lesions.

show abstract

Section: Discussionsupporting

confidence: 54%

Proteomic profile of saliva and plasma from women with impalpable breast lesions

et al. 2016

View full text Add to dashboard Cite

show abstract

“…There are 4 allelic variants of the apolipoprotein E gene (e1, e2, e3, e4,) with the e4 gene being associated with breast cancer among Asian population (49). Apolipoprotein E has been shown to be upregulated in breast cancer in prediagnostic serum (50). Thus, it seems that the combination of high amounts of n-3 and Tamoxifen downregulated apolipoprotein E in the plasma of rats, which could contribute to the increased efficacy of the combination in comparison to the individual interventions.…”

Section: Discussionmentioning

confidence: 99%

Proteomic Changes Induced by Effective Chemopreventive Ratios of n-3:n-6 Fatty Acids and Tamoxifen against MNU-Induced Mammary Cancer in the Rat

Skibinski

Thompson

Das

et al. 2013

Cancer Prevention Research

View full text Add to dashboard Cite

We used a proteomic approach to gain insights into the mechanisms of protection at the protein level by a high n-3:n-6 ratio in the absence and presence of Tamoxifen. Four groups were treated with 1-methyl-1-nitrosourea (MNU) and fed the following diets with varied n-3:n-6 ratios; group 1 ¼ 1:1; groups 2 and 3 ¼ 10:1 and 25:1, respectively; group 4: (25:1) plus Tamoxifen (1 mg/kg diet). The plasma from six rats/group was pooled and analyzed with the isobaric tags for relative and absolute quantitation method; 148 proteins were identified with 95% confidence by ProteinPilot 4.0. In plasma of rats fed 10:1, 25:1 n-3:n-6, and 25:1 plus Tamoxifen, the number of proteins that met our criteria (P 0.05, error factor 2) were 10, 14, and 19 proteins, respectively. Selected proteins were further validated by Western blotting. Compared to 1:1, both 10:1 and 25:1 diets upregulated vitamin D binding protein, gelsolin, and 14-3-3 sigma, reported to have tumor suppressive effects, whereas alpha-1B-glycoprotein, which has been reported to be elevated in the serum of breast cancer patients was decreased. Compared to 25:1, the 25:1 plus Tamoxifen diet downregulated apolipoprotein E, haptoglobin, and inter-a-inhibitor H4 heavy chain. Ingenuity pathway analysis determined that the trends of specific proteins were related to lipid metabolism in the 25:1 n-3:n-6 group, whereas the 25:1 n-3:n-6 plus Tamoxifen group included proteins involved in cancer and inflammation. Our results show that several proteins were altered in a manner consistent with chemoprevention. Such proteins may serve as biomarkers to monitor efficacy of n-3 and Tamoxifen in future clinical chemoprevention trials. Cancer Prev Res; 6(9); 979-88. Ó2013 AACR.

show abstract

“…These markers have been previously described as potential biomarker candidates associated with multiple cancer types in other studies. For instance, AFM was reported as a potential biomarker for ovarian cancer (21) and breast cancer (22), where AFM may play a role in the progression of cancer. Plasma AFM concentrations were validated by Western blotting and immunoassays in patients with ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Discovery and Validation of Biomarkers That Distinguish Mucinous and Nonmucinous Pancreatic Cysts

et al. 2015

View full text Add to dashboard Cite

The use of advanced imaging technologies for the identification of pancreatic cysts has become widespread. However, accurate differential diagnosis between mucinous cysts (MC) and nonmucinous cysts (NMC) consisting of pseudocysts (NMC1) and nonmucinous neoplastic cysts (NMC2) remains a challenge. Thus, it is necessary to develop novel biomarkers for the differential diagnosis of pancreatic cysts. An integrated proteomics approach yielded differentially expressed proteins in MC that were verified subsequently in 99 pancreatic cysts (21 NMC1, 41 NMC2, and 37 MC) using a method termed GeLC-stable isotope dilution-multiple reaction monitoring-mass spectrometry (GeLC-SID-MRM-MS) along with established immunoassay techniques. We identified 223 proteins by nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC/MS-MS). Nine candidate biomarkers were identified, including polymeric immunoglobulin receptor (PIGR), lipocalin 2 (LCN2), Fc fragment of IgG-binding protein (FCGBP), lithostathine-1-alpha (REG1A), afamin (AFM), chymotrypsin C (caldecrin; CTRC), amylase, alpha 2B (pancreatic; AMY2B), lectin, galactoside-binding, soluble, 3 binding protein (LGALS3BP), and chymotrypsin-like elastase family, member 3A (CELA3A), which were established as biomarker candidates for MC. In particular, we have shown that a biomarker subset, including AFM, REG1A, PIGR, and LCN2, could differentiate MC not only from NMC (including NMC1) but also from NMC2. Overall, the MS-based comprehensive proteomics approach used in this study established a novel set of candidate biomarkers that address a gap in efforts to distinguish early pancreatic lesions at a time when more successful therapeutic interventions may be possible. Cancer Res; 75(16); 3227-35. Ó2015 AACR.

show abstract

Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study

Cited by 78 publications

References 35 publications

Proteomic profile of saliva and plasma from women with impalpable breast lesions

Proteomic profile of saliva and plasma from women with impalpable breast lesions

Proteomic Changes Induced by Effective Chemopreventive Ratios of n-3:n-6 Fatty Acids and Tamoxifen against MNU-Induced Mammary Cancer in the Rat

Discovery and Validation of Biomarkers That Distinguish Mucinous and Nonmucinous Pancreatic Cysts

Contact Info

Product

Resources

About